Bayer Reports Unexpected Q3 Earnings Growth Driven by Pharmaceuticals

Bayer AG reported an unexpected increase in third-quarter operating results, driven by a recovery and strong growth in its Pharmaceuticals division. CEO Bill Anderson said the division had reached a turning point, and Bayer raised its full-year 2026 pharmaceutical margin expectations. Pharma’s performance helped offset ongoing market pressures in the agricultural and consumer-health divisions.